Paper42350656
TRIM32-mediated ABI2 downregulation promotes anoikis resistance and metastasis by regulating EMT in lung adenocarcinoma.
Liu Y and 3 others. Cell Mol Life Sci, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. TRIM32-mediated ABI2 downregulation promotes anoikis resistance and metastasis by regulating EMT in lung adenocarcinoma. Papers, record 42350656. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42350656
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- TRIM32-mediated ABI2 downregulation promotes anoikis resistance and metastasis by regulating EMT in lung adenocarcinoma.
- PubMed
Topics20
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Anoikis | Major topic |
| Lung Neoplasms | Major topic |
| Ubiquitin-Protein Ligases | Major topic |
| Tripartite Motif Proteins | Major topic |
| Adenocarcinoma of Lung | Major topic |
| Epithelial-Mesenchymal Transition | Major topic |
| Adaptor Proteins, Signal Transducing | Major topic |
| Humans | |
| Animals | |
| Down-Regulation | |
| Ubiquitination | |
| Gene Expression Regulation, Neoplastic | |
| Cell Line, Tumor | |
| Mice, Nude | |
| Neoplasm Metastasis | |
| Mice | |
| Female | |
| Male | |
| Mice, Inbred BALB C | |
| Transcription Factors |
Source PubMed
Grants5
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 82370055 | National Natural Science Foundation of China | PubMed | ||
| 2020YFC2008600 | Key Technologies Research and Development Program | PubMed | ||
| Lung Cancer, ID: z027002 | National Multidisciplinary Cooprative Diagnosis and Treatment Capacity Building Project for Major Diseases | PubMed | ||
| 2025ZZTS0238 | Fundamental Research Funds for the Central Universities of Central South University | PubMed | ||
| CX20250358 | Hunan Provincial Innovation Foundation for Postgraduate | PubMed |
Source PubMed
References42
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 38994085 | Mitochondrial dysfunction significantly contributes to the sensitivity of tumor cells to anoikis and their metastatic potential. | Heliyon | 2024 | https://conductscience.org/library/papers/38994085 | PubMed |
| 2 | 38937761 | Inhibition of ABI2 ubiquitination-dependent degradation suppresses TNBC cell growth via down-regulating PI3K/Akt signaling pathway. | Cancer Cell Int | 2024 | https://conductscience.org/library/papers/38937761 | PubMed |
| 3 | 29665353 | Tripartite motif 31 promotes resistance to anoikis of hepatocarcinoma cells through regulation of p53-AMPK axis. | Exp Cell Res | 2018 | https://conductscience.org/library/papers/29665353 | PubMed |
| 4 | 40350473 | Digoxin promotes anoikis of circulating cancer cells by targeting Na+/K+-ATPase α3-isoform. | Cell Death Dis | 2025 | https://conductscience.org/library/papers/40350473 | PubMed |
| 5 | 30378152 | Expression and the potential functions of TRIM32 in lung cancer tumorigenesis. | J Cell Biochem | 2019 | https://conductscience.org/library/papers/30378152 | PubMed |
| 6 | 20493758 | ABA perception and signalling. | Trends Plant Sci | 2010 | https://conductscience.org/library/papers/20493758 | PubMed |
| 7 | 30464531 | TRIM32 overexpression improves chemoresistance through regulation of mitochondrial function in non-small-cell lung cancers. | Onco Targets Ther | 2018 | https://conductscience.org/library/papers/30464531 | PubMed |
| 8 | 40186594 | Novel therapeutic approaches for non-small cell lung cancer: an updated view. | J Drug Target | 2025 | https://conductscience.org/library/papers/40186594 | PubMed |
| 9 | 40294841 | Anoikis resistance in Cancer: Mechanisms, therapeutic strategies, potential targets, and models for enhanced understanding. | Cancer Lett | 2025 | https://conductscience.org/library/papers/40294841 | PubMed |
| 10 | 39654601 | Exploring the Mechanisms, Biomarkers, and Therapeutic Targets of TRIM Family in Gastrointestinal Cancer. | Drug Des Devel Ther | 2024 | https://conductscience.org/library/papers/39654601 | PubMed |
| 11 | 35589677 | TGF-β1/SH2B3 axis regulates anoikis resistance and EMT of lung cancer cells by modulating JAK2/STAT3 and SHP2/Grb2 signaling pathways. | Cell Death Dis | 2022 | https://conductscience.org/library/papers/35589677 | PubMed |
| 12 | 36230714 | Anoikis-Associated Lung Cancer Metastasis: Mechanisms and Therapies. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/36230714 | PubMed |
| 13 | 31907338 | Downregulation of ABI2 expression by EBV-miR-BART13-3p induces epithelial-mesenchymal transition of nasopharyngeal carcinoma cells through upregulation of c-JUN/SLUG signaling. | Aging (Albany NY) | 2020 | https://conductscience.org/library/papers/31907338 | PubMed |
| 14 | 36427397 | CPT1A promotes anoikis resistance in esophageal squamous cell carcinoma via redox homeostasis. | Redox Biol | 2022 | https://conductscience.org/library/papers/36427397 | PubMed |
| 15 | 33207810 | Emerging Concepts of Hybrid Epithelial-to-Mesenchymal Transition in Cancer Progression. | Biomolecules | 2020 | https://conductscience.org/library/papers/33207810 | PubMed |
| 16 | 37344626 | Epigenetic regulation of hybrid epithelial-mesenchymal cell states in cancer. | Oncogene | 2023 | https://conductscience.org/library/papers/37344626 | PubMed |
| 17 | 35719027 | PRR16/Largen Induces Epithelial-Mesenchymal Transition through the Interaction with ABI2 Leading to the Activation of ABL1 Kinase. | Biomol Ther (Seoul) | 2022 | https://conductscience.org/library/papers/35719027 | PubMed |
| 18 | 39895782 | Training and experimental validation a novel anoikis- and epithelial‒mesenchymal transition-related signature for evaluating prognosis and predicting immunotherapy efficacy in gastric cancer. | J Cancer | 2025 | https://conductscience.org/library/papers/39895782 | PubMed |
| 19 | 18632609 | Tripartite motif protein 32 facilitates cell growth and migration via degradation of Abl-interactor 2. | Cancer Res | 2008 | https://conductscience.org/library/papers/18632609 | PubMed |
| 20 | 39389179 | GDF15 enhances anoikis resistance and metastasis of gastric cancer through protective autophagy. | Cell Signal | 2024 | https://conductscience.org/library/papers/39389179 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ABI2 | 10152 | PubTator's text mining | https://conductscience.org/library/genes/10152 | NCBI Gene |
| TRIM32 | 22954 | PubTator's text mining | https://conductscience.org/library/genes/22954 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Cited by
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42350656
GET https://conductscience.org/api/papers/v1/42350656/references?page=2